Long-term oral corticosteroid (LTOCS) use has been found to be lower in Mexican patients than globally and may be associated with impact to critical health outcomes, with potentially oral corticosteroid-related diseases found to be less common in Mexican patients. These findings are reported in the real-world study, “ Severe asthma patients’ characteristics in Mexico versus International Severe Asthma Registry (ISAR) Global ” , recently published in Current Allergy and Asthma

The real-world study, “ Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach ”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice . Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach instead of the pre-defined thresholds used in prior studies. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα)  was associated